Reuters: Private Equity: Bridgepoint plans Aenova drugs group sale -sources

Reuters: Private Equity Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bridgepoint plans Aenova drugs group sale -sources May 22nd 2012, 10:21 By Simon Meads and Arno Schuetze LONDON/FRANKFURT | Tue May 22, 2012 6:21am EDT LONDON/FRANKFURT May 22 (Reuters) - Private equity group Bridgepoint has picked Morgan Stanley to sell Aenova, hoping to pull in more than 400 million euros ($510 million) for the German vitamins and generic prescription drugs maker, two people familiar with the situation said. The auction of Aenova is planned to kick off in the autumn, the people said, and is expected to attract rival vitamin makers such as German chemicals group BASF and Dutch supplements maker DSM, as well as private equity firms. Bridgepoint was unavailable for comment. Aenova and Morgan Stanley declined to comment.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions